ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?

Size: px
Start display at page:

Download "ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?"

Transcription

1 ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be discussed during this presentation. The speaker served as a content expert for the ASCP geriatrics pharmacy review (GPR) course. 1

2 PHARMACIST OBJECTIVES 1. Given a patient case, analyze psychotropic regulatory compliance in long term care using the CMS State Operations Manual. 2. Compare and contrast the efficacy of at least 2 different antipsychotics for the treatment of behavioral and psychological symptoms of dementia. 3. Given a patient case, evaluate the appropriateness of antipsychotic prescription and recommend alternatives based on evidence-based literature. TECHNICIAN OBJECTIVES 1. Identify common dose ranges for antipsychotics when used to treat behavioral and psychological symptoms of dementia. 2. Relate antipsychotic adverse effects to their receptor affinities. OUTLINE Background Antipsychotic use in dementia Antipsychotic literature evaluation Alternatives to antipsychotics Treatment approach to behavioral and psychological symptoms of dementia (BPSD) Case breakout session Conclusion 2

3 BACKGROUND DEFINITION AND EPIDEMIOLOGY OF DEMENTIA EPIDEMIOLOGY Figure: International, A.s.D. World Alzheimer Report; DEMENTIA DEFINITION Neurocognitive disorder (per DSM-V) Diagnosis Minor Neurocognitive Disorder Major Neurocognitive Disorder *Not due to: delirium, other mental disorder Characteristics Moderate cognitive decline Does not interfere with ADLs Significant cognitive decline Interferes with ADLs American Psychiatric Association. Neurocognitive Disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5 th ed

4 DIAGNOSIS TYPES OF DEMENTIA Alzheimer s disease (AD) Vascular Mixed Lewy Body Parkinson s Fronto- Temporal BPSD DEFINITION Hallucinations Repetitive Activities Delusions BPSD Wandering Paranoia Aggression 4

5 Dementia population will experience one or more BPSD Unpaid caregiver hours per year provided to those with dementia Quick Facts. Alzheimer s Association. Cincinnati, OH. Modified from: Walters SA. 1/2016. Which form of dementia is characterized by decreased attention, motor dysfunction, and well-formed hallucinations? ANTIPSYCHOTIC USE IN DEMENTIA RISK AND GUIDELINES FOR USE 5

6 ANTIPSYCHOTICS BLACK BOX WARNING WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. Increased risk of death due to: o Stroke o Sudden cardiac death and heart failure o Infections NNH = 83 This BBW was placed on all atypical antipsychotics in 2005 and then was extended to include typical antipsychotics in 2008 Need to weigh risks versus benefits Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center Slide Credit: Walters SA. 1/2016. THE RISK REALIZED 5.5 Million People with AD 90% with BPSD 4.95 Million People with AD and BPSD Antipsychotic Treatment: NNH = 83 ~60,000 potential deaths/year due to antipsychotics Modified from: Walters SA. 1/2016. AMERICAN PSYCHIATRIC ASSOCIATION Assessment Assess type, frequency, severity, pattern, and timing of symptoms Assess potentially modifiable contributors Benefits and Risks Only use when symptoms are severe, dangerous and/or cause significant distress to patient Implement and review response to non-pharmacologic interventions Antipsychotics Use and Monitoring Initiate at low dose and titrate to effective dose If no clinically significant response in 4 weeks, discontinue Discuss dose titrations with patient s surrogate decision maker Avoid short-acting haloperidol for chronic use American Psychiatric Association. Am J Psychiatry 173:5:

7 AMERICAN GERIATRICS SOCIETY A systematic review of prospective studies including 6 single-agent and 7 comparison studies Small study populations and limited methodologies throughout the various studies Rates of delirium resolution in non-medication intervention studies were similar to that of the antipsychotic studies in this review This review does not support using antipsychotics for delirium in hospitalized elderly patients Flaherty JH, Gonzales JP, Dong B. J Am Geriatr Soc. 59 Suppl 2:S269-76, 2011 Nov. CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) REGULATIONS F757: Unnecessary Medications Any drug when used: In excessive dose For excessive duration Without adequate monitoring Without adequate indications for use In the presence of adverse consequences which indicate the dose should be reduced or discontinued Any combinations of the above Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP CMS REGULATIONS (cont.) F758: Psychotropic Drugs Definition: any drug that affects brain activities associated with mental processes and behavior Antipsychotic Antidepressant Antianxiety Hypnotic Others: anticonvulsants, antihistamines, anticholinergics, antiemetics, muscle relaxants, mood stabilizers, NMDA receptor modulators Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP

8 CMS REGULATIONS (cont.) F758: Psychotropic Drugs [Gradual Dose Reduction (GDR)] Most Psychotropics (including antipsychotics) Twice in first year in two separate quarters Annually Sedative/Hypnotics/Benzodiazepines Quarterly Clinical Contraindication: Resident s symptoms returned or worsened after the most recent GDR attempt AND Attempted further dose reduction would likely impair resident s function or cause psychiatric instability Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP CMS REGULATIONS UPDATES F758: Psychotropic Drugs [Duration] PRN Psychotropic Orders Specific condition diagnosed and documented in the medical record 14 day limit unless rationale in medical record PRN Antipsychotic Orders 14 day limit (no exceptions) Renewal requires attending or prescriber evaluation Centers for Medicare and Medicaid Services. State Operations Manual Appendix PP What are the most common causes of death related to antipsychotic use in elderly individuals with dementia? 8

9 ANTIPSYCHOTIC LITERATURE EVALUATION FIRST AND SECOND GENERATION ANTIPSYCHOTICS CATIE-AD METHODS Design Double-blind, placebo-controlled Intervention: Olanzapine v. Quetiapine v. Risperidone v. Placebo Population Outcomes Inclusion: Ambulatory Alzheimer disease, MMSE 5-26, BPSD symptoms for at least 4 weeks Exclusion: Psychotic disorder, delirium, other dementia, substance abuse; new acetylcholinesterase inhibitor or antidepressant medication Primary: Time until discontinuation of treatment for any reason Secondary: Attainment of minimal or greater improvement in CGIC scale at 12 weeks Safety: Weight, prolactin, glucose, cholesterol, triglycerides at weeks 12, 24, 36 Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15): CATIE-AD CHARACTERISTICS Characteristic Olanzapine (n=99) Quetiapine (n=94) Risperidone (n=84) Placebo (n=139) MMSE (n) Total NPI, total (n) Delusions (%) Hallucinations (%) Agitation (%) Medications Antidepressant (%) Atypical Antipsychotic (%) Cholinesterase Inhibitor(%) Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15):

10 CATIE-AD OUTCOMES: EFFICACY Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15): CATIE-AD OUTCOMES: SAFETY Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15): CONCLUSIONS No large clinical benefit of treatment for BPSD with atypical antipsychotic medications compared to placebo Discontinuation of antipsychotic for any reason was similar between groups Discontinuation due to lack of efficacy: Placebo Quetiapine > Risperidone and Olanzapine Discontinuation due to adverse effects: Olanzapine > Quetiapine and Risperidone > Placebo Schneider LS, Tariot PN, Dagerman KS, et al. NEJM 2006;355(15):

11 ANTIPSYCHOTICS Typical Antipsychotics (haloperidol, thioridazine, thiothixene, chlorpromazine, trifluoperazine) Haloperidol: Some efficacy for aggression (but not agitation) with drop-out rates due to adverse effects. Thioridazine: Improvement in anxiety, but clinical significance unclear Recommendation: No clear evidence for the effectiveness of any typical antipsychotic in the treatment of dementiarelated symptoms. Haloperidol ( mg/dose) may show some improvement in aggression. Atypical Antipsychotics (clozapine, olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole) Risperidone: Both 1mg and 2mg doses showed equiefficacious improvements in BPSD, but the 2 mg dose resulted in significantly higher adverse events. Olanzapine: Only low-dose (5mg/day) showed improvements in overall agitation/aggression, hallucinations and delusions. Quetiapine: No significant improvements on BPSD. Aripiprazole: Mixed results with unclear clinical significance. Recommendation: Risperidone (1mg/dose) and olanzapine (5-10mg/dose) are modestly effective at improving these dementia-related symptoms. Sink K, et al. JAMA: 2005;293(5): ; Gareri P, et al. J Clin Psychopharmacol 2014;34: Modified from: Walters SA. 1/2016. EFFICACY SUMMARY: ATYPICALS Aripiprazole Olanzapine Quetiapine Risperidone Dementia Overall Dementia Psychosis Dementia Agitation /- +/ /- ++ Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center Drug ANTIPSYCHOTIC DOSING GUIDE Starting Dose (mg/day) Max Maintenance Dose (mg/day) Special Dosage Forms Aripiprazole ODT, L, IM Haloperidol C, L, IM Olanzapine ODT, L, IM Quetiapine SR Risperidone ODT, L Abbreviations: C = oral concentrate, L = liquid, IM = short-acting intramuscular, ODT = oral disintegrating tablet, SR = sustained release Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center

12 RELATIVE ADVERSE EFFECTS Receptor Haloperidol Aripiprazole Olanzapine Quetiapine Risperidone D 2 Dopamine EPS 5HT 2A Serotonin Anti-EPS 5HT 2C Serotonin Weight Gain α 1 Adrenergic Sedation, Hypotension H 1 Histamine Sedation, Weight Gain M 1 Muscarinic Delirium, Anticholinergic (partial agonist) Richelson E. J Clin Psychiatry 2010;71(9): Receptor Haloperidol Aripiprazole Olanzapine Quetiapine Risperidone Hypertriglyerceridemia QT Prolongation +/-? +/- +/- +/- Urinary Incontinence RELATIVE ADVERSE EFFECTS (cont.) Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center PIMAVANSERIN 5-HT 2A inverse agonist and antagonist, low affinity for 5-HT 2C receptors No dopaminergic activity FDA approved for psychosis in Parkinson s disease (PD) Dosage: 34mg by mouth Daily Strong CYP3A4 inhibitors: 17mg by mouth Daily Adverse Effects: Orthostatic hypotension, CNS depression, Peripheral edema, Nausea, Constipation, QTc prolongation (rare) 12

13 PIMAVANSERIN CLINICAL TRIALS PARKINSON S PSYCHOSIS 1 Methods: Phase 3 placebocontrolled blinded RCT Inclusion Criteria: Age >40, diagnosed PD 1 year, severe psychotic symptoms weekly, MMSE 21 Primary Outcome: Change in SAPS-PD score from baseline to Day 43 37% v. 14% SAPS-PD improvement (p<0.001) No significant effects on movements, orthostasis ALZHEIMER S PSYCHOSIS 2 Methods: Phase 2 placebocontrolled double-blinded RCT Inclusion Criteria: Age >50, diagnosed AD and psychosis, severe psychotic symptoms weekly x2 weeks, NPI 6, NH placement 4 weeks without discharge Primary Outcome: Change in NPI- NH psychotic score from baseline to Day v NPI-NH psychosis score (p=0.045) No difference in total NPI scores 1. Cummings J, Isaacson S, Mills R, et al. Lancet 2014;383: Ballard C, Banister C, Khan Z, et al. 2018;17: Pharmacists: In the CATIE-AD trial, which antipsychotic was not statistically significantly different from placebo for the outcome of discontinuation due to lack of efficacy? Technicians: Which antipsychotic studied for dementia with BPSD is associated with the least extrapyramidal symptoms? ALTERNATIVE TO ANTIPSYCHOTICS NON-PHARMACOLOGIC AND PHARMACOLOGIC OPTIONS 13

14 KNOW YOUR ABCS OF DEMENTIA A B C Activator What happened just before B? Behavior What was the patient doing? Who was present? Where was this happening? When was this happening? Consequence What happened just after B? Did this make the behavior better or worse? Star-VA Program: The ABCs of Dementia. Presentation by French JL, Obrien S. REVERSIBLE CAUSES OF BPSD Unmet physical needs Pain Infection Dehydration/nutrition Sleep disturbances Constipation Unmet psychological needs Loneliness Boredom Environmental causes Noise Lighting Caregiver approaches Lack of cues/prompts Psychiatric causes Depression Anxiety Delirium Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center NON-PHARMACOLOGIC ALTERNATIVES Cognitive/Emotion-oriented therapies Reminiscence/ Simulated presence therapy Validation therapy Sensory stimulation Massage and touch, Music therapy, Snoezelen therapy Behavior management Patient-specific behavioral evaluation Animal-assisted therapy Exercise O Neil M et al. Department of Veteran Affairs; Modified from: Walters SA. 1/

15 NON-PHARMACOLOGIC EXAMPLES Cues, prompts, reminders Simplified daily routine Speak in clear, simple phrases Do not challenge Personalized or group activities Eliminate distractors Reduce stress Reduce clutter Reduce sources for threats Adapt environment to reduce exit-seeking Individualized music Reassure Improving Antipsychotic Appropriateness in Dementia Patients [Internet].: Iowa Geriatric Education Center ALTERNATIVES NON-PHARMACOLOGIC Sensory stimulation Behavior management techniques Animal-assisted therapy Exercise PHARMACOLOGIC Antidepressants Cholinesterase inhibitors Mood stabilizers NDMA-receptor antagonists Memantine Dextromethorphan/ Quinidine ANTIDEPRESSANTS Antidepressants (Selective Serotonin Reuptake Inhibitors [SSRIs]) (fluoxetine, trazodone, citalopram, and sertraline) Sertraline: No effect on neuropsychiatric symptoms, but did show an improvement in depression in dementia patients. 1 Citalopram: - A significant improvement in agitation and mood lability were seen compared to placebo in a 17 day study. 1 - Further studies supported these findings of clinically significant improvement of agitation/aggression and caregiver distress with citalopram. 2,3 - The CitAD trial further showed efficacy for agitation in AD; however, target dose was citalopram 30mg daily, which is associated with a higher risk of QT prolongation. 3 Recommendation: Although they are well-tolerated, antidepressants do not appear to be very effective overall in treating neuropsychiatric symptoms. Citalopram 20mg daily may be an option for agitation symptoms. 1. Sink K, et al. JAMA: 2005;293(5): ; 2. Pollock BG et al. Am J Geriatr Psychiatry. 2007;15(11): ; 3. Porsteinsson A et al. JAMA. 2014;311(7): Slide Credit: Walters SA. 1/

16 CHOLINESTERASE INHIBITORS (AChEIs) Cholinesterase Inhibitors (AChEIs) (rivastigmine, donepezil, and galantamine) Donepezil: Conflicting results from 4 RCTs. One showed improvements in agitation/aggression. Another showed improvement in depression, anxiety, and apathy. 1 Continuation of AChEIs in moderate-severe dementia may hasten cognitive and functional decline. 2 Initiation of AChEIs may reduce BPSD, but clinical significance unknown. 3 Galantamine: Only the 16mg/dose showed a small but significant improvement in the Neuropsychiatric Inventory (NPI) scale compared to placebo. 1 Recommendation: Donepezil and galantamine may provide some small improvement that may not prove clinically significant Sink K, et al. JAMA: 2005;293(5): Howard R et al. N J Engl Med 2014;366(10): Campbell N, et al. Clin Inter Aging 2008;3(4): Slide Credit: Walters SA. 1/2016. MOOD STABILIZERS Mood Stabilizers (valproate and carbamazepine) Carbamazepine: One 6 week study showed an improvement in agitation compared to placebo; although, another study showed no improvements in these target symptoms. Valproate: No significant improvement and increased risk of ADRs. Recommendation: The use of valproate is not recommended, due to lack of efficacy and significantly higher ADRs. There is currently not enough data to support the use of carbamazepine. Sink K, et al. JAMA: 2005;293(5): Slide Credit: Walters SA. 1/2016. NMDA RECEPTOR ANTAGONISTS Memantine Memantine: Mixed results from 2 RCTs. 1 One showed no difference in symptoms. The other showed a significant difference compared to placebo due to the placebo-group s declining health and increased symptoms. Recommendation: There does not appear to be a direct role for memantine in the management of BPSD. Dextromethorphan/ Quinidine (DM/Q) (Nuedexta ) DM/Q: One phase 2, 10 week RCT for treatment of agitation in Alzheimer s disease. A statistically significant improvement was seen in agitation/aggression per the NPI. 2 Recommendation: Dextromethorphan/quinidine may be considered as a second or third line agent specifically for significant agitation in those with Alzheimer s disease. Drugdrug interactions with CYP2D6 should be evaluated. 1. Sink K, et al. JAMA 2005;293(5): Cummings JL et al. JAMA 2015;314(12): Slide Credit: Walters SA. 1/

17 BPSD TREATMENT ALGORITHM BPSD Yes Nonpharmacologic No SSRI AChEI with or without memantine Consider DM/Q Atypical antipsychotic^ SSRI Carbamazepine DM/Q Evaluate for reversible causes Depression or anxiety? Consult specialist *If intervention is effective, monitorfor reoccurrence and adverse effects ^ Consider pimavanserin for patientswith PD andpsychosis. Modified from: Sink K, et al. JAMA: 2005;293(5): What non-pharmacologic strategies have been proven effective to decrease BPSD? CASE BREAKOUT SESSION 17

18 CASE DISCUSSION A B C Activator What happened just before B? Behavior What was the patient doing? Who was present? Where was this happening? When was this happening? Consequence What happened just after B? Did this make the behavior better or worse? Star-VA Program: The ABCs of Dementia. Presentation by French JL, Obrien S. Which classes of non-antipsychotic psychotropics have at least a moderate quality of evidence to support their use for BPSD? Hopefully, not these drugs! CONCLUSION BPSD is a common symptom associated with dementia. Use of antipsychotics for the treatment of BPSD is associated with an increased risk for death. Antipsychotic use in long term care facilities is highly regulated by CMS and GDR documentation is required. Non-pharmacologic interventions should always be attempted first. Evidenced based medicine indicates some benefits of aripiprazole, olanzapine, and risperidone for BPSD. Some SSRIs and AChEIs may also be helpful in managing BPSDrelated syndromes. 18

19 MORE INFORMATION: Iowa Geriatric Education Center: IA-ADAPT Toolkit: 19

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences

More information

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017 Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic

More information

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public

More information

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer

More information

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University

More information

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate

More information

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.

More information

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms

More information

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological

More information

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4 Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.

More information

Psychotropic Strategies Handout Package

Psychotropic Strategies Handout Package Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles

More information

Antipsychotics for Dementia Under Control or Over-Prescribed?

Antipsychotics for Dementia Under Control or Over-Prescribed? Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most

More information

Psychotropic Medication. Including Role of Gradual Dose Reductions

Psychotropic Medication. Including Role of Gradual Dose Reductions Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which

More information

Nuplazid. (pimavanserin) New Product Slideshow

Nuplazid. (pimavanserin) New Product Slideshow Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:

More information

Pharmacotherapy of Dementia Behaviors

Pharmacotherapy of Dementia Behaviors This Clinical Resource gives subscribers additional insight related to the Recommendations published in June 2017 ~ Resource #330601 Pharmacotherapy of Dementia Behaviors (Also see our chart specific to

More information

Management of the Acutely Agitated Long Term Care Patient

Management of the Acutely Agitated Long Term Care Patient Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia

More information

Pharmacological Treatment of Aggression in the Elderly

Pharmacological Treatment of Aggression in the Elderly Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question

More information

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize

More information

Any interventions, where RCTs in PD are not available, are not included in the tables.

Any interventions, where RCTs in PD are not available, are not included in the tables. Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in

More information

9/11/2012. Clare I. Hays, MD, CMD

9/11/2012. Clare I. Hays, MD, CMD Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management

More information

BEHAVIORAL PROBLEMS IN DEMENTIA

BEHAVIORAL PROBLEMS IN DEMENTIA BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and

More information

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,

More information

Treatment of behavioral and psychological symptoms of dementia: a systematic review

Treatment of behavioral and psychological symptoms of dementia: a systematic review Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms

More information

Assessment and management of behavioral and psychological symptoms of dementia

Assessment and management of behavioral and psychological symptoms of dementia Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,

More information

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also

More information

Behavioral and Psychological Symptoms of dementia (BPSD)

Behavioral and Psychological Symptoms of dementia (BPSD) Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management

More information

Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.

Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D. Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS

More information

ONCE-DAILY DOSING WITH NUPLAZID

ONCE-DAILY DOSING WITH NUPLAZID YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication

More information

Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director

Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director Objectives Differentiate between delirium, terminal restlessness, and dementia related agitation

More information

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia

More information

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer

More information

Improving Antipsychotic Appropriateness in Dementia Patients. Disclosures

Improving Antipsychotic Appropriateness in Dementia Patients. Disclosures Improving Antipsychotic Appropriateness in Dementia Patients Ryan Carnahan, Pharm.D., M.S., BCPP Assistant Professor (Clinical) The University of Iowa College of Public Health Department of Epidemiology

More information

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed

More information

Objectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition

Objectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change

More information

DEMENTIA AND MEDICATION

DEMENTIA AND MEDICATION DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,

More information

Corporate Presentation August 6, 2015

Corporate Presentation August 6, 2015 Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events

More information

Improving Antipsychotic Appropriateness in Dementia Patients. Disclosures. The Challenge 4/21/2014

Improving Antipsychotic Appropriateness in Dementia Patients. Disclosures. The Challenge 4/21/2014 Improving Antipsychotic Appropriateness in Dementia Patients Ryan Carnahan, Pharm.D., M.S., BCPP Associate Professor (Clinical) The University of Iowa College of Public Health Department of Epidemiology

More information

Gradual Dose Reduction and Medication Tapering: A Clinical Perspective

Gradual Dose Reduction and Medication Tapering: A Clinical Perspective Gradual Dose Reduction and Medication Tapering: A Clinical Perspective Recent changes in the State Operations Manual put new emphasis on attempts to gradually reduce the dose of certain medications namely

More information

Antipsychotic Use in the Elderly

Antipsychotic Use in the Elderly Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure

More information

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,

More information

From Neurodevelopment to Neurodegeneration: Behavioral Issues

From Neurodevelopment to Neurodegeneration: Behavioral Issues From Neurodevelopment to Neurodegeneration: Behavioral Issues Amer M. Burhan, MBChB, FRCPC Associate Professor and Chair Geriatric Psychiatry at Western U Objectives Discuss factors that contribute to

More information

Dementia: Managing Difficult Behaviors. No conflicts of interest. Off-label medication use will be discussed during this talk.

Dementia: Managing Difficult Behaviors. No conflicts of interest. Off-label medication use will be discussed during this talk. Dementia: Managing Difficult Behaviors No conflicts of interest. Off-label medication use will be discussed during this talk. 1 Types of Neurocognitive Disorder Alzheimer s Disease Vascular Frontotemporal

More information

Lewy Body Disease. Dementia Education for the First Responder July 27, 2017

Lewy Body Disease. Dementia Education for the First Responder July 27, 2017 Lewy Body Disease Dementia Education for the First Responder July 27, 2017 Dylan Wint, M.D. NV Energy Chair for Brain Health Education Cleveland Clinic Lou Ruvo Center for Brain Health OUTLINE Lewy body

More information

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points

More information

Antidepressants. Dr Malek Zihlif

Antidepressants. Dr Malek Zihlif Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric

More information

Appendix N: Research recommendations

Appendix N: Research recommendations Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist

More information

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding

More information

Use of Psychotropic Medications in Older Adults with Dementia!

Use of Psychotropic Medications in Older Adults with Dementia! Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue

More information

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY

More information

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics

More information

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,

More information

New Medications in Early Psychosis

New Medications in Early Psychosis New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,

More information

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be

More information

Addressing Difficult Behaviors in Dementia

Addressing Difficult Behaviors in Dementia Addressing Difficult Behaviors in Dementia GEORGE SCHOEPHOERSTER, MD GERIATRICIAN GENEVIVE/CENTRACARE CLINIC Objectives By the end of the session, you will be able to: 1) Explain the role of pain management

More information

Drugs used to relieve behavioural and psychological symptoms in dementia

Drugs used to relieve behavioural and psychological symptoms in dementia alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

Management of Behavioral Problems in Dementia

Management of Behavioral Problems in Dementia Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives

More information

Community Pharmacy Dementia Audit

Community Pharmacy Dementia Audit Community Pharmacy Dementia Audit Introduction To comply with the NHS contractual requirements associated with the Clinical Governance Essential Service, pharmacy contractors must perform an annual practice

More information

Up to 90% of people with dementia experience

Up to 90% of people with dementia experience Focus on CME at the University of Calgary Getting Aggressive with Dementia Adrienne Cohen, MD, BSc, FRCPC Presented at Behaviour Problems in the Elderly, video-audio conference, 2003 Up to 90% of people

More information

Medications for treating people with dementia: summary of evidence on cost-effectiveness

Medications for treating people with dementia: summary of evidence on cost-effectiveness Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017

More information

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) CLeAR Webinar February 14, 2014 Paula Diaz (Pharm) Carol Ward MD Carol Ward Tertiary Mental Health IHA Hillside Centre (Acute Tertiary Mental

More information

PSYCHOSIS: CHALLENGING ISSUES IN PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS

PSYCHOSIS: CHALLENGING ISSUES IN PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS PSYCHOSIS: CHALLENGING ISSUES IN PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS Objectives Identify neurobiological substrates associated with Parkinson s disease psychosis Describe the differences

More information

MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE

MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN

More information

Recognition and Management of Behavioral Disturbances in Dementia

Recognition and Management of Behavioral Disturbances in Dementia Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic

More information

Rational Medication Use in Dementia

Rational Medication Use in Dementia Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this

More information

New England QIN-QIO Reducing Unnecessary Antipsychotic Medications Affinity Group Call Thursday, January 19 th 3-4:00 pm. Presenters.

New England QIN-QIO Reducing Unnecessary Antipsychotic Medications Affinity Group Call Thursday, January 19 th 3-4:00 pm. Presenters. New England QIN-QIO Reducing Unnecessary Antipsychotic Medications Affinity Group Call Thursday, January 19 th 3-4:00 pm Call-In Information: 1-888-895-6448 Code: 7362894 Log-In Information: https://qualidigm.adobeconnect.com/affinity/

More information

Diagnosis and Treatment of Alzhiemer s Disease

Diagnosis and Treatment of Alzhiemer s Disease Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised

More information

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors

More information

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used

More information

Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical

Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression

More information

Medication alternatives for behavioural disturbance

Medication alternatives for behavioural disturbance Neurology 13 Medication alternatives for behavioural disturbance Many patients with dementia will in the later stages develop distressing behavioural symptoms. Antipsychotics are commonly used to treat

More information

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Pari Deshmukh MD Triple board-certified psychiatrist (Boards of psychiatry, addiction medicine, integrative

More information

Restrained use of antipsychotic medications:

Restrained use of antipsychotic medications: Balanced information for better care Restrained use of antipsychotic medications: Rational management of irrationality These drugs are commonly prescribed in conditions for which there is little evidence

More information

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the

More information

Nuplazid. Nuplazid (pimavanserin) Description

Nuplazid. Nuplazid (pimavanserin) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.03 Subject: Nuplazid Page: 1 of 4 Last Review Date: June 22, 2018 Nuplazid Description Nuplazid (pimavanserin)

More information

Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts

Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day

More information

Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance

Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance American Association for Geriatric Psychiatry Los Angeles, CA March 2013 Maureen C. Nash, MD, MS, FAPA Medical Director,

More information

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, 2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,

More information

The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State

The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State RAI/MDS Coordinator Objectives Upon completion of this training,

More information

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia

More information

THIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes

THIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold

More information

A Basic Approach to Mood and Anxiety Disorders in the Elderly

A Basic Approach to Mood and Anxiety Disorders in the Elderly A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict

More information

Chapter 161 Antipsychotics

Chapter 161 Antipsychotics Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in

More information

LTC Research Influencing Practice

LTC Research Influencing Practice LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts

More information

Full details and resource documents available:

Full details and resource documents available: Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,

More information

Prescribing for people with dementia. Carol Paton Chief Pharmacist April 2009

Prescribing for people with dementia. Carol Paton Chief Pharmacist April 2009 Prescribing for people with dementia Carol Paton Chief Pharmacist April 2009 What are the issues? 1. Minimising cognitive side effects from prescribed medicines 2. Prescribing memory enhancing drugs 3.

More information

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency

More information

Assessment and management of behavioral. B ehavior al and psychological symptoms of dementia are STATE OF THE ART REVIEW

Assessment and management of behavioral. B ehavior al and psychological symptoms of dementia are STATE OF THE ART REVIEW Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,

More information

Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study

Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Stewart G. Albert, MD, George T. Grossberg, MD, Papan J. Thaipisuttikul,

More information